Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca and Jazz Pharmaceuticals, Inc.

1st Annual Virtual Tumor Board®: Navigating Novel Emerging Therapeutic Approaches for the Management of SCLC Across Lines of Care

Release Date: July 27, 2020
Expiration Date: July 27, 2021

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in small cell lung cancer (SCLC) provides an overview of clinical data leading to recent approvals, as well as emerging approaches and management of treatment-related adverse events. The heart of this program includes several case-based, tumor board discussions addressing the application of new agents in a variety of clinical settings in SCLC.

This educational activity is an archive of the live virtual symposium held on July 15, 2020.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca and Jazz Pharmaceuticals, Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward medical oncologists and radiation oncologists involved in the treatment and management of patients with lung cancer. Nurse practitioners (NPs), nurses, physician assistants (PAs), pharmacists, researchers, and other healthcare professionals interested in the treatment of lung cancer may also participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Apply new standards of care for patients with newly diagnosed and relapsed/refractory SCLC
  • Assess strategies to mitigate and manage treatment-related adverse events in patients with SCLC
  • Evaluate novel agents and approaches for patients with extensive-stage and limited-stage SCLC
  • Discuss the status of techniques to select patients and optimize therapy among patients with SCLC

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Roy S. Herbst, MD, PhD
Roy S. Herbst, MD, PhD
Ensign Professor of Medicine (Medical Oncology) Professor of Pharmacology
Chief, Medical Oncology
Associate Director, Translational Research Yale Cancer Center
Yale School of Medicine
New Haven, CT

Disclosures: Grant Research Support: AstraZeneca, Eli Lilly and Company, Genentech/Roche, Merck & Co; Consultant: AbbVie, ARMO BioSciences, AstraZeneca, Biodesix, Bolt Biotherapeutics, Bristol Myers Squibb, Cybrexa, Eli Lilly and Company, EMD Serono, Genentech/Roche, Genmab, Halozyme, Heat Biologics, I-MAB Biopharma, Immunocore, Infinity Pharmaceuticals, Loxo Oncology, Merck & Co, Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Pfizer, Sanofi, Seattle Genetics, Shire plc, Spectrum Pharmaceuticals, Symphogen, Takeda, Tesaro, Tocagen; Other:Board member: Junshi Biosciences

Primo N. Lara, Jr., MD
Primo N. Lara, Jr., MD
Director, University of California Davis Comprehensive Cancer Center
Professor of Medicine
Executive Associate Dean for Cancer Programs
Codman-Radke Endowed Chair for Cancer Research
UC Davis School of Medicine
Deputy Chair SWOG Cancer Research Network
Sacramento, CA

Disclosures: Primo N. Lara, Jr., MD has no relevant financial relationships with commercial interests.

Jhanelle Gray, MD
Jhanelle Gray, MD
Department Chair, Program Leader & Senior Member
Thoracic Oncology
Co-Leader, Chemical Biology and Molecular Medicine Program
Associate Professor, Oncologic Sciences
University of South Florida, Morsani College of Medicine
Moffitt Cancer Center
Tampa, Florida

Disclosures: Grant Research Support: AstraZeneca; Bristol-Myers Squibb, Boehringer Ingelheim; GI Therapeutics: Genentech; Novartis; Pfizer: Ludwig Institute of Cancer Research; Consultant: AstraZeneca; Bristol-Myers Squibb, Inivata; EMD Serono; Merck; Novartis; Blueprint Medicine

Karen Kelly, MD, MD
Karen Kelly, MD
Associate Director for Clinical Research,
Professor of Medicine,
Jennifer Harmon Tegley and Erica Renee Harmon Endowed Professor of Clinical Research
UC Davis Comprehensive Cancer Center
Sacramento, CA

Disclosures: Grant Research Support: AbbVie, Celgene, EMD Serono, Five Prime, Genentech, Lilly, Lycera, Novartis, Regeneron, Transgene; Consultant: AbbVie, AstraZeneca, G1 Therapeutics, Janssen, Lilly, Merck, Takeda, Regeneron; Other: UpToDate Author

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By